{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:41:04Z","timestamp":1790811664575,"version":"4.1.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Risk of acute pancreatitis is possible with several weight management medications including glucagon like peptide-1 receptor agonists. Acute pancreatitis has not been reported with the phentermine\/topiramate combination product used as an appetite suppressant for chronic weight management.\n                    <jats:bold>Summary:<\/jats:bold>\n                    A 71-year-old male initiated phentermine\/topiramate extended-release capsules for assistance with weight loss. Approximately 4 days after initiation, he presented to the emergency department with sudden mid-epigastric pain, nausea, and vomiting. He was subsequently diagnosed with acute pancreatitis, which was confirmed with imaging. Contributory factors for development of acute pancreatitis were ruled out including gallstones, alcohol intake, and hypertriglyceridemia. The phentermine\/topiramate product was discontinued. Symptoms improved within 2 days, and his lipase was within normal limits at discharge. The Naranjo adverse drug reaction score was used to assess causality with a total score of 6, suggesting a probable cause for this adverse drug event.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This report describes the presentation of acute pancreatitis shortly after initiation of phentermine\/topiramate extended-release capsules for assistance with weight loss. Pancreatitis has not been previously reported with this combination product to the author\u2019s knowledge and impacts future prescribing for alternative agents.\n                  <\/jats:p>","DOI":"10.1177\/08971900261416787","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:45:17Z","timestamp":1768934717000},"page":"475-479","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Presentation of Acute Pancreatitis After Initiation of Phentermine\/Topiramate for Weight Loss: An Adverse Drug Event Case Report"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9414-1431","authenticated-orcid":false,"given":"Michelle","family":"Balli","sequence":"first","affiliation":[{"name":"Pharmacy Department, Veterans Health Care System of the Ozarks"},{"name":"Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_3_6_2_2","volume-title":"Obesity and Overweight","author":"World Health Organization","unstructured":"World Health Organization. Obesity and Overweight. c2025 May 7 [cited 2025 May 29]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57232"},{"key":"e_1_3_6_5_2","volume-title":"QSYMIA\u00ae (phentermine and topiramate extended-release capsules) [Highlights of Prescribing Information]","author":"VIVUS LLC.","year":"2025","unstructured":"VIVUS LLC. QSYMIA\u00ae (phentermine and topiramate extended-release capsules) [Highlights of Prescribing Information]. Campbell, CA: VIVUS LLC; 2025."},{"key":"e_1_3_6_6_2","volume-title":"TOPAMAX\u00ae (topiramate) [Highlights of Prescribing Information]","author":"Janssen Pharmaceuticals Inc.","year":"2025","unstructured":"Janssen Pharmaceuticals Inc. TOPAMAX\u00ae (topiramate) [Highlights of Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2025."},{"key":"e_1_3_6_7_2","unstructured":"Pfizer Inc. MOTRIN\u00ae oral tablets ibuprofen oral tablets [prescribing information]. Pfizer New York NY April 2007."},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP43558"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000999"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.12.029"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302779"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.20317"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-23630"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000621"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000430433"},{"issue":"6","key":"e_1_3_6_17_2","article-title":"Naltrexone-associated acute pancreatitis","volume":"18","author":"Verma R","year":"2016","unstructured":"Verma R. Naltrexone-associated acute pancreatitis. Prim Care Companion CNS Disord. 2016;18(6).","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_6_18_2","volume-title":"WEGOVY\u00ae (Semaglutide) [Highlights of Prescribing Information]","author":"Novo Nordisk Inc","year":"2025","unstructured":"Novo Nordisk Inc. WEGOVY\u00ae (Semaglutide) [Highlights of Prescribing Information]. Plainsboro, NJ: Novo Nordisk Inc; 2025."},{"key":"e_1_3_6_19_2","volume-title":"OZEMPIC\u00ae (Semaglutide) [Highlights of Prescribing Information]","author":"Novo Nordisk Inc","year":"2025","unstructured":"Novo Nordisk Inc. OZEMPIC\u00ae (Semaglutide) [Highlights of Prescribing Information]. Plainsboro, NJ: Novo Nordisk Inc; 2025."},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13924"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.8526"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900261416787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900261416787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900261416787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:18:56Z","timestamp":1787494736000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900261416787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/08971900261416787"],"URL":"https:\/\/doi.org\/10.1177\/08971900261416787","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}